11.8 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 LARTRUVO + Doxorubicin Study Design αα References: 1. Oncology 2. Lancet 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 OVERALL SURVIVAL LARTRUVO + DOXORUBICIN DOXORUBICIN ALONE 66 62 60 57 52 51 50 47 43 41 41 39 33 32 29 26 16 16 15 8 3 3 1 1 0 Doxorubicin Alone 67 61 51 46 43 37 34 32 28 23 21 19 19 15 13 13 10 7 6 6 5 3 2 1 0 3.8 INCREASE 0 2 4 6 8 10 12 14 16 18 20 22 NUMBER AT RISK LARTRUVO + Doxorubicin 66 44 34 23 18 10 7 3 2 1 1 0 67 34 24 11 7 5 5 3 2 1 1 0 Doxorubicin Alone 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 LARTRUVO + DOXORUBICIN DOXORUBICIN ALONE There were 39 (59%) deaths among patients taking LARTRUVO + doxorubicin compared to 52 (78%) deaths among patients taking doxorubicin alone. MEDIAN OS COMPARED TO 14.7 MONTHS WITH DOXORUBICIN ALONE, AN INCREASE OF 11.8 MONTHSP MEDIAN PFS COMPARED TO 4.4 MONTHS WITH DOXORUBICIN ALONE 2 OVERALL SURVIVAL (OS) LARTRUVO + DOXORUBICIN DOXORUBICIN ALONE 18.2% 7.5% 0% 20% 40% 60% 80% 100% Visit LARTRUVO.com/hcp to learn more LARTRUVO LARTRUVO + DOXORUBICIN MORE THAN DOUBLED ORR COMPARED TO DOXORUBICIN ALONE: 18.2% VS 7.5% >2x IMPROVEMENT ORR=complete response (CR) + partial response (PR).
20109GA
To see the actual publication please follow the link above